CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment

CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment

24th February 2021

Cardiff, UK – CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs. This expansion will be supported by a £3 million investment over the next two years and the opening of a secondary site in Dagenham, East London in April 2021. The new facility will help to increase the UK’s scientific exports and solidify the UK as a centre for excellence in pharmaceutical research and development (R&D).

CatSci’s enhanced capabilities will include addressing new modalities and asset classes, such as oligonucleotides, alongside additional capacity for GMP analytical testing. By adding better solid form characterisation to its material science offerings and increasing its preformulation capabilities, CatSci aims to break down the barriers between drug substance and drug product to improve medicines development. By following a science-led approach, with the end product in mind, CatSci will expedite the development and launch of new medicines.

To lead these expansion plans, CatSci has appointed Dr Nigel Richardson as the Director of Analytical Technology and New Modalities and Dr Robert Dennehy as Director of Crystallisation and Solid State. 

Dr Richardson will also take up the position of Site Director at the new analytical facility in Dagenham, utilising his expertise in analytical technology, oligonucleotide development and previous role as Senior Director within the CMC Analytical Division at GlaxoSmithKline (GSK). 

Dr Dennehy, whose experience includes leading the Particle Sciences team at GSK,  will develop the workflows for CatSci’s material science lab and act as a consultant for the transformation of CatSci’s solid form capabilities.

The facility and capabilities expansion will help CatSci on its path to becoming a fully integrated CMC company, one that continually evolves to provide ‘more and better’ for customers bringing best-in-class therapeutics to patients in need. It also follows the current trend for expansion within the buoyant UK based life science sector. Innovation in this area will create more jobs and help to solidify the UK as a key player in the global pharmaceutical development industry. 

Dr Ross Burn, CEO, said: “It is a fantastic time to be expanding our business in the UK pharmaceutical R&D space. These increased capabilities will significantly contribute to CatSci’s current offerings and will be a continuation of the already successful £1.3 million expansion we’ve just completed. We’re confident that this next step will offer strategic value to our customers’ journey from molecule to medicine and strengthen the UK economy.”

Dr Robert Dennehy, Director of Crystallisation and Solid State said: “I’m honoured to be a part of this next stage in CatSci’s evolution, applying my expertise in solid state to accelerate the development of life-changing therapeutics.” 

Dr Nigel Richardson, Director of Analytical Technology and New Modalities, said: “It’s a really exciting time to be working in the process R&D and life sciences sector. I’m delighted to be helping CatSci to deliver excellence in measurement science so that our customers can make the right decisions first time and every time.”